

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/046703 A1

- | | | |
|---|--|---|
| (51) International Patent Classification ⁷ : | A61K 35/74,
38/00, 35/00 | (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW. |
| (21) International Application Number: | PCT/CA2004/001968 | |
| (22) International Filing Date: | 15 November 2004 (15.11.2004) | |
| (25) Filing Language: | English | |
| (26) Publication Language: | English | |
| (30) Priority Data: | 2,448,843 | 13 November 2003 (13.11.2003) CA |
| (71) Applicant (for all designated States except US): | BIO-K PLUS INTERNATIONAL INC. [CA/CA]; 495, boulevard Armand-Frappier, Laval, Québec H7V 4A7 (CA). | |
| (72) Inventors; and | | |
| (75) Inventors/Applicants (for US only): | BELIVEAU, Richard [CA/CA]; 266 Wilson, Ile-des-soeurs, Québec H3E 1L8 (CA). LUQUET, François-Marie [FR/FR]; 41, rue Aristide Briand, F-91400 Orsay (FR). | |
| (74) Agent: | ROBIC; Centre CDP Capital, 1001, square Victoria - Bloc E - 8eme Etage, Montréal, Québec H2Z 2B7 (CA). | |

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/046703 A1

(54) Title: USE OF STRAIN OF BACILLUS AND BYPRODUCTS THEREOF FOR INHIBITING FORMATION OF BLOOD VESSELS

(57) Abstract: A lactic composition containing at least a bacterial strain selected from the group consisting of *Lactobacillus acidophilus*, *Lactobacillus casei* and a mixture of *Lactobacillus acidophilus* and *Lactobacillus casei*, and a whole broth of the bacterial strain or the mixture of the bacterial strains, is useful for the prevention or treatment of disorders which are angiogenesis dependant. Both the lactic composition and its supernatant can be used for prevention or treatment of angiogenesis dependant disorders. The supernatant of the lactic composition exhibits antiangiogenic properties.